Cooper LJ, Topp MS, Serrano LM, Gonzalez S, Chang WC, Naranjo A, Wright C, Popplewell L, Raubitschek A, Forman SJ, Jensen MC: T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood 101:1637, 2003.
Jensen MC, Cooper LJ, Wu AM, Forman SJ, Raubitschek A: Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy 5:131, 2003.
Sundaresan G, Yazaki PJ, Shively JE, Finn RD, Larson SM, Raubitschek AA, Williams LE, Chatziioannou AF, Gambhir SS, Wu AM: 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J Nuclear Med. 44:1962, 2003.
Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, Yamauchi DM, Wilczynski S, Ikle DN, Wu AM, Yazaki PJ, Shively JE, Doroshow JH, Raubitschek AA: A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res. 9:5842, 2003.
Olafsen T, Cheung CW, Yazaki PJ, Li L, Sundaresan G, Gambhir SS, Sherman MA, Williams LE, Shively JE, Raubitschek AA, Wu AM: Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng Des Sel. 17:21, 2004.
Wong JYC, Chu DZ, Williams LE, Yamauchi DM, Ikle DN, Kwok CS, Liu A, Wilczynski S, Colcher D, Yazaki PJ, Shively JE, Wu AM, and Raubitschek AA: A pilot trial evaluating a 123I labeled 80 kD engineered anti-CEA antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin Cancer Res. 10:5014, 2004.
Yazaki PJ, Sherman MA, Shivley JE, Ikle D, Williams LE, Wong JYC, Colcher D, Wu AM and Raubitschek AA: Humanization of the anti-CEA T84.66 antibody based on crystal structure data. Protein Engineering Design & Selection 17, 481, 2004.
Wong, J.Y., Chum D.Z., Williams L.E., Yamauchi, D.M., Ikle, D.N., Kwok, C.S., Liu, A., Wilczynski, S., Colcher, D., Yazaki, P.J., Shively, J.E., Wu, A.M., Raubitschek, A.A.: Pilot trial evaluating an 123I-labeled 80 kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin Cancer Res. 10:5014, 2004.
Cooper, L.J., Al-Kadhimi, Z., DiGiusto, D., Kalos, M., Colcher, D., Raubitschek, A., Forman, S.J., Jensen, M.C.: Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies. Blood Cells Mol Dis. 33:83, 2004.
Kahlon, K.S., Brown, C., Cooper, L.J., Raubitschek, A., Forman, S.J., Jensen, M.C.: Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 64:9160, 2004.
Gillies, S.D., Lan, Y., Williams, S., Carr, F., Forman, S., Raubitschek, A., Lo, K.M: An anti-CD20-IL2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood 105:3972, 2005.
Kenanova V, Olafsen T, Crow DM, Sundaresan G, Subbarayan M, Carter NH, Ikle DN, Yazaki PJ, Chatziioannou AF, Gambhir SS, Williams LE, Shively JE, Colcher D, Raubitschek AA and Wu AM: Tailoring the pharmacokinetics of engineered antibody fragments.Biodistribution and small animal PET imaging studies of anti-CEA scFv-Fc and variants. Cancer Res. 65:622, 2005.
Schnell R, Dietlein M, Staak JO, Borchmann P, Schomaecker K, Fischer T, Eschner W, Hansen H, Morschhauser F, Schicha H, Diehl V, Raubitschek A and Engert A: Treatment of Refractory Hodgkin's Lymphoma Patients with an [(131)I]-Labeled Murine Anti-CD30 Monoclonal Antibody. J Clin Oncol. 23:4669, 2005.Nademanee A, Forman S, Molina A, Fung H, Smith D, Dagis A, Kwok C, Yamauchi D,
Anderson AL, Falk P, Krishnan A, Kirschbaum M, Kogut N, Nakamura R, O'Donnell M, Parker P, Popplewell L, Pullarkat V, Rodriguez R, Sahebi F, Smith E, Snyder D., Stein A, Spielberger R, Zain J, White C, Raubitschek A: A Phase 1/2 Trial of High-Dose Yttrium-90 Ibritumomab Tiuxetan in Combination with High-Dose Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Patients with Poor-Risk or Relapsed Non-Hodgkins Lymphoma (NHL). Blood 106:2896, 2005.
Brown, C.E., Wright, C.L., Naranjo, A., Vishwanath, R.P., Chang, W.C., Olivares, S., Wagner, J.R., Bruins, L., Raubitschek, A., Cooper, L.J., Jensen, M.C.: Biophotonic cytotoxicity assay for high-throughput screening of cytolytic killing. J Immunol Methods 297: 39, 2005.
Li L, Yazaki PJ, Anderson AL, Crow D, Colcher D, Wu AM, Williams LE, Wong JYC, Raubitschek A, Shively JE: Improved Biodistribution and Radioimmunoimaging with Poly(ethylene glycol)-DOTA-Conjugated Anti-CEA Diabody. Bioconjugate Chem. 17:68, 2006.
Wong JYC, Chu DZ, Williams LE, Liu A, Zhan J, Yamauchi DM, Wilczynski S, Wu AM, Yazaki PJ, Shively JE, Leong L, Raubitschek AA: A Phase I Trial of Y-90-DOTA-Anti-CEA Chimeric T84.66 (cT84.66) Radioimmunotherapy in Patients with Metastatic CEA-Producing Malignancies. Cancer Biother Radiopharm. 21:88, 2006.
This is a partial list. Full publications list available upon request. Information on this page may be self-reported and is subject to change at any time. Last reviewed: 07/08.
